Immunomodulatory function of major histocompatibility complex-derived peptides

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 3, 1996, Pages 262-268

  Murphy, Barbara ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; AUTOIMMUNITY; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE SYSTEM; ISOANTIGENS; T-LYMPHOCYTES;

EID: 0029932954     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199605000-00012     Document Type: Review

References (58)

1. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC: The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigen. Nature 1987, 329:506-512.
2. Brown JH, Jardelzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364:33-39
3. Sloan-Lancaster J, Evavold B, Allen P: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993, 363:156-159.
4. Chicz RM, Urban RG, Gorga JC, Vignali AA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993, 178:27-47.
5. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ Vignali AA, Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogenous in size. Nature 1992, 358:764-768.
6. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E, Grey HM Sette A. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992, 256:1817-1820.
7. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P: T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990, 322:510-517.
8. Sayegh MH, Watschinger B, Carpenter CB: Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994, 57:1295-1302.
9. Shoskes, DA, Wood KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 1994, 15:32-38.
10. Benichou G, Takizawa AP, Olson AC, McMillan M, Sercarz EE: Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992, 175:305-308.
11. Fangmann J, Dalchau R, Sawyer GJ, Priestly CA, Fabre JW: T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur J Immun 1992, 22:1525-1530.
12. Watschinger B, Gallon L, Carpenter CB, Sayegh MH: Mechanisms of allorecognition: recognition by in vivo primed T-cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994, 57:572-577.
13. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB: Indirect pathway of allorecognition: the occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute allograft rejection and its inhibition by conventional immunosuppression. Transplantation 1995, 59:612-616.
14. Murphy B, Auchincloss H Jr, Carpenter CB, Sayegh MH: T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation 1996 (in press).
15. Fangmann J, Dalchau R, Fabre JW: Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992, 175:1521-1529.
16. Auchincloss HJ, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH: The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A 1993, 90:3373-3377.
17. Lee RS, Grusby ML, Glimsher LH, Winn HJ, Auchincloss HJ: Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994, 179:865-872.
18. Benham AM, Sawyer GJ, Fabre JW: Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation 1995, 59:1028-1032.
19. Braun YM, McCormack A, Webb G, Batchelor RJ: Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation 1993, 55:117-182.
20. Liu Z, Sun Y, Xi Y, Maffei A, Reed E, Harris P, Suciu-Foca N: Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993, 177:1643-1650.
21. Sayegh MH, Carpenter MH: Role of indirect allorecognition in allograft rejection. Int Rev Immun 1996, 13:221-229.
22. Sayegh MH, Krensky AM: Novel immunotherapeutic strategies using MHC derived peptides. Kidney Int 1996, 49(suppl):S13-S20. A good comprehensive review of the role of MHC peptides as immuno-modulators in transplantation.
23. + T cell and B cell responses after cardiac allograft rejection. Transplantation 1995, 59:401-410.
24. Benham A, Fabre JW: Fine specificity of peptide determinants for indirect T cell recognition of class I MHC alloantigens. Transplantation 1994, 58:1236-1240.
25. a rat class I major histocompatibility antigens induce specific alloimmunity. Transplantation 1995, 60:602-610. An elegant study using hepatoma cells transfected for either intact membrane bound or soluble truncated rat MHC class I to demonstrate the ability of these molecules to enhance to alloimmune response when administered before transplantation.
26. Oluwole SF, Chowdhury NC, Jin M, Hardy MA: Induction of transplantation tolerance in rat cardiac allografts by intrathymic inoculation of allogeneic soluble peptides. Transplantation 1993, 56:1523-1527.
27. Qian T, Schachner R, Brendel M, Kong S, Alejandro R: Induction of donor specific tolerance to rat islet allografts by inthrathymic inoculation of solubilized spleen cell membrane antigens. Diabetes 1993, 42:1544-1546.
28. Oluwole SF, Jin M-X, Chowdhury NC, Ohajekwe OA: Effectiveness of intrathymic inoculation of soluble antigens in the induction of specific unresponsiveness to rat islet allografts without transient recipient immunosuppression. Transplantation 1994, 58:1077-1084.
29. Shirwan H: Induction of allograft tolerance with major histocompatability complex peptides [Abstract]. Am Soc Transplant Phys 1995, 107.
30. Ohajekwe O, Chowdhury N, Fiedor P, Hardy M, Oluwole S: Transplantation tolerance to rat cardiac and islet allografts by posttransplant intrathymic inoculation of soluable alloantigens. Transplantation 1995, 60:1139-1143. This study demonstrates that the administration of soluble alloantigen when given as late as 7 days post-transplantation in combination with a single dose of antilymphocyte serum on the day of transplant results in permanent graft survival. This has particularly important implications for the clinical applicability of intrathymic injection as a method of inducing tolerance.
31. Clayberger C, Parham P, Rothbard J, Ludwig DS, Schoolnik GK, Krensky AM: HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 1987, 330:763-765.
32. Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnik GK, Krensky AM: Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha-2 domain of HLA-A2. Nature 1987, 325:625-628.
33. Clayberger C. Lyu S-C, Derkruyff R, Parham P, Krensky A: Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T lymphocyte immune responses in vitro. J Immun 1994, 53:946-951.
34. Clayberger C, Lyu S-C, Pouletty P, Krensky AM: Peptides corresponding to T cell receptor HLA contact regions inhibit class I restricted immune responses. Transplant Proc 1993, 25:477-478.
35. Nisco S, Vriens P, Hoyt G, Lyu S-C, Farfan F, Pouletty P, Krensky AM, Clayberger C: Induction of allograft tolerance in rats by an HLA-class I derived peptide and cyclosporine A. J Immun 1994, 152:3786-3792.
36. Cuturi M-C, Josien R, Douillard P, Pannetier C, Cantarovich D, Smit H, Menoret S, Pouletty P, Clayberger C, Soulillou J-P: Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a.75-84) from the α1 helices of the first domain of HLA-B7 01. Transplantation 1995, 59:661-669.
37. Buelow R, Veyron P, Clayberger C, Pouletty P, Touraine J-L: Prolongation of skin allograft survival in mice following administration of allotrap. Transplantation 1995, 59:455-460.
38. Woo J, Gao L, Cornejo M-C, Buelow R: A synthetic dimeric HLA class I peptide inhibits cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Transplantation 1995, 60:1156-1163. A peptide derived from the ́ chain of HLA B2702 (residues 75-84) in combination with low dose cyclosporine resulted in long-term cardiac graft survival in mice. A dimeric form of this peptide was shown to inhibit not only cytotoxic T and NK cells, as in the case for the monomeric form, but also to inhibit anit-CD3 T cell proliferation and the mixed lymphocyte response. The dimeric peptide also had more potent effects in vivo.
39. Gao L, Woo J, Buelow R: Both L- and D-isomers of Allotrap 2702 prolong survival in mice. J Heart Lung Trans 1996 (in press).
40. Nossener E, Goldberg J, Lyu S-C, Naftzger C, Clayberger C, Krensky A: HLA derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J Exp Med 1996, 183:1-10. The mechanism of action of the inhibitory HLA-derived peptides were investigated. The study indicated that these proteins are binding to members of the HSP 70 family, and there was a direct correlation between the peptide effects on lymphocyte function, their induction of increased intracellular calcium, and the binding to the HSP-70 molecules.
41. Sayegh MH, Perico N, Imberti O, Hancock WW, Carpenter CB, Remuzzi G: Thymic recognition of class II MHC allopeptides induces donor specific unresponsiveness to renal allografts. Transplantation 1993, 56:461-465.
42. Sayegh MH, Perico N, Gallon L, Imberti O, Hancock WW, Remuzzi G, Carpenter CB: Mechanisms of acquired thymic unresponsiveness to renal allografts: thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994, 58:125-130.
43. Hancock WW, Khoury SJ, Carpenter CB, Sayegh MH: Differential effects of oral versus intrathymic administration of polymorphic MHC class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response. Am J Pathol 1994, 144:1149-1158.
44. Remuzzi G, Noris M, Benigni A, Imberti O, Sayegh MH, Perico N: Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts triggered by thymic recognition of histocompatibility allopeptides. J Exp Med 1994, 180:1967-1972.
45. Sayegh MH, Turka LA: T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995, 6:1143-1150.
46. H2 cytokines.
47. Khoury SJ, Sayegh MH, Gallon L, Hancock WW, Carpenter CB, Weiner HL: Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalotigenic peptide. J Exp Med 1993, 178:559-566.
48. Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL: Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 1995, 181:357-366. This study investigates the mechanisms of acquired thymic tolerance in an autoimmune model. The results showed that thymic dendritic-enriched cells mediate the induction of tolerance. Interaction of primed T cells with thymic dendritic-enriched cells resulted in anergy or deletion of these cells leading to antigen-specific systemic tolerance.
49. Sayegh MH: Applicability of acquired thymic unresponsiveness in humans [Editorial]. J Nephrol 1994, 7:3-4.
50. Remuzzi G. Perico N, Carpenter CB, Sayegh MH: The thymic way to transplantation tolerance. J Am Soc Nephrol 1995, 5:1639-1646.
51. Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh MH, Nussenblatt RB, Trentham DE, Hafler DA: Oral tolerance: immunologic mechanisms and treatment of murine and human organ specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immun 1994, 12:809-837.
52. Sayegh MH, Zhang ZJ, Hancock WW, Kwok CA, Carpenter CB, Weiner HL: Orally administered alloantigen down-regulates the immune response to histocompatibility antigens and prevents sensitization by skin allografts. Transplantation 1992, 53:163-166.
53. Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB: Oral but not intravenous alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 1993, 55:1112-1118.
54. Sayegh MH, Khoury SK, Hancock WW, Weiner HL, Carpenter CB: Induction of immunity and oral tolerance with polymorphic class II MHC allopeptides in the rat Proc Natl Acad Sci U S A 1992, 89:7762-7766.
55. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB: Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci 1996 (in press).
56. s antibodies and thereby prevent the development of EAE. When given after the development of disease this peptide was shown to decrease the relapse rate.
57. Murphy B, Akalin E, Watschinger B, Carpenter CB, Sayegh MH: Inhibition of the alloimmune response with synthetic non-polymorphic class II MHC peptides. Transplant Proc 1995, 27:409.
58. Murphy B, Waaga A, Carpenter C, Sayegh M: Synthetic peptides derived from highly conserved regions of the MHC class II alpha chain immunomodulate the alloimmune response in vitro [Abstract]. J Am Soc Nephrol 1995, 5:1368.